Iqvia (NYSE:IQV)‘s stock had its “hold” rating reaffirmed by analysts at SunTrust Banks in a note issued to investors on Monday. They presently have a $110.00 target price on the medical research company’s stock. SunTrust Banks’ target price suggests a potential upside of 6.25% from the stock’s current price.
Several other equities analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Iqvia from a “buy” rating to a “hold” rating in a report on Friday. Evercore ISI assumed coverage on shares of Iqvia in a report on Thursday. They issued an “outperform” rating and a $112.00 price target on the stock. Mitsubishi UFJ Financial Group assumed coverage on shares of Iqvia in a report on Friday, December 15th. They issued a “neutral” rating and a $112.00 price target on the stock. TheStreet upgraded shares of Iqvia from a “c+” rating to a “b” rating in a report on Wednesday, December 13th. Finally, KeyCorp reiterated a “sector weight” rating and issued a $100.00 price target on shares of Iqvia in a report on Friday, November 10th. Eight research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $107.55.
Iqvia (NYSE IQV) traded up $0.53 on Monday, hitting $103.53. 664,492 shares of the stock traded hands, compared to its average volume of 1,110,854. Iqvia has a 12-month low of $74.80 and a 12-month high of $110.67. The company has a current ratio of 1.22, a quick ratio of 1.22 and a debt-to-equity ratio of 1.29. The firm has a market capitalization of $21,470.00, a P/E ratio of 356.98, a P/E/G ratio of 1.42 and a beta of 0.61.
In other news, insider Ari Bousbib sold 46,080 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $101.79, for a total transaction of $4,690,483.20. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider James H. Erlinger III sold 10,000 shares of the stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $101.21, for a total value of $1,012,100.00. The disclosure for this sale can be found here. Insiders have sold a total of 8,806,558 shares of company stock worth $898,716,708 in the last ninety days. Corporate insiders own 6.40% of the company’s stock.
Several large investors have recently made changes to their positions in IQV. Exxonmobil Investment Management Inc. TX purchased a new position in shares of Iqvia during the 4th quarter valued at approximately $2,266,000. DnB Asset Management AS purchased a new position in shares of Iqvia during the 4th quarter valued at approximately $8,813,000. First Citizens Bank & Trust Co. purchased a new position in shares of Iqvia during the 4th quarter valued at approximately $1,067,000. Franklin Street Advisors Inc. NC purchased a new position in shares of Iqvia during the 4th quarter valued at approximately $7,446,000. Finally, Nisa Investment Advisors LLC purchased a new position in shares of Iqvia during the 4th quarter valued at approximately $920,000. Hedge funds and other institutional investors own 95.84% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.themarketsdaily.com/2018/01/22/iqvia-iqv-receives-hold-rating-from-suntrust-banks.html.
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.